France: These 5 Drugs Face Patent Expirations and Generic Entry in 2025 - 2026

DrugPatentWatch^® Estimated Loss of Exclusivity Dates in France

These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.

Summary: France: These 5 Drugs Face Patent Expirations and Generic Entry in 2025 - 2026

Subscribe to access the full database, or Get Started Free
Tradename	Ingredient	Estimated Entry Opportunity Date
EPIDUO	adapalene; benzoyl peroxide	2026-07-13
EPIDUO FORTE	adapalene; benzoyl peroxide	2026-07-13
PRESTALIA	amlodipine besylate; perindopril arginine	2026-02-28
>Tradename	>Ingredient	>Estimated Entry Opportunity Date

Details: France: These 5 Drugs Face Patent Expirations and Generic Entry in 2025 - 2026

When can EPIDUO (adapalene; benzoyl peroxide) generic drug versions launch?

Generic name: adapalene; benzoyl peroxide
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 13, 2026
Generic Entry Controlled by: France Patent 2,903,603

EPIDUO is a drug marketed by Galderma Labs Lp and Galderma LabsThere are four patents protecting this drug and two Paragraph IV challenges.

This drug has sixty-eight patent family members in twenty-five countries. There has been litigation on patents covering EPIDUO

See drug price trends for EPIDUO.

The generic ingredient in EPIDUO is adapalene; benzoyl peroxide. There are twelve drug master file entries for this API. Thirteen suppliers are listed for this generic product. Additional details are available on the adapalene; benzoyl peroxide profile page.

When can EPIDUO FORTE (adapalene; benzoyl peroxide) generic drug versions launch?

Generic name: adapalene; benzoyl peroxide
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 13, 2026
Generic Entry Controlled by: France Patent 2,903,603

EPIDUO FORTE is a drug marketed by Galderma Labs. There has been litigation on patents covering EPIDUO FORTE

See drug price trends for EPIDUO FORTE.

The generic ingredient in EPIDUO FORTE is adapalene; benzoyl peroxide. There are twelve drug master file entries for this API. Thirteen suppliers are listed for this generic product. Additional details are available on the adapalene; benzoyl peroxide profile page.

When can PRESTALIA (amlodipine besylate; perindopril arginine) generic drug versions launch?

Generic name: amlodipine besylate; perindopril arginine
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: February 28, 2026
Generic Entry Controlled by: France Patent 2,897,866

PRESTALIA is a drug marketed by Adhera. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty patent family members in twenty-seven countries. There has been litigation on patents covering PRESTALIA

The generic ingredient in PRESTALIA is amlodipine besylate; perindopril arginine. There are fifty drug master file entries for this API. Additional details are available on the amlodipine besylate; perindopril arginine profile page.

When can KOSELUGO (selumetinib sulfate) generic drug versions launch?

Generic name: selumetinib sulfate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 21, 2025
Generic Entry Controlled by: France Patent 21C1051

KOSELUGO is a drug marketed by Astrazeneca. There are eight patents protecting this drug.

This drug has two hundred and one patent family members in forty-five countries. There has been litigation on patents covering KOSELUGO

See drug price trends for KOSELUGO.

The generic ingredient in KOSELUGO is selumetinib sulfate. One supplier is listed for this generic product. Additional details are available on the selumetinib sulfate profile page.

When can KORSUVA (difelikefalin acetate) generic drug versions launch?

Generic name: difelikefalin acetate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: November 10, 2026
Generic Entry Controlled by: France Patent 22C1054

KORSUVA is a drug marketed by Vifor Intl. There are twelve patents protecting this drug.

This drug has fifty-three patent family members in twenty-seven countries. There has been litigation on patents covering KORSUVA

See drug price trends for KORSUVA.

The generic ingredient in KORSUVA is difelikefalin acetate. One supplier is listed for this generic product. Additional details are available on the difelikefalin acetate profile page.